Summa Equity portfolio company Sengenics is acquired by Standard BioTools
- News
- Changing Demographics
November 21, 2024, Stockholm: Impact investment firm Summa Equity (“Summa”) today announced the acquisition of Sengenics Corporation Pte Ltd (“Sengenics”) by Standard BioTools Inc. (Nasdaq: LAB).
Sengenics’ technology has opened new avenues in biomedical research, and it’s been rewarding to support its journey as a part of our Changing Demographics strategy. Integrating Sengenics’ antibody profiling with the SomaScan platform holds strong potential for advancing disease research globally. With Standard BioTools’ expertise in scaling and commercializing products, the combination will enable biomedical researchers to develop the next generation of medicines in a faster, more efficient manner.
Christoph Waer, Partner in Summa
Sengenics is a functional proteomics company enabling the detection of autoantibody biomarkers and protein interactions. Founded in 2008, the innovative immunoproteomics company leverages its KREXTM protein-folding technology to enable precise antibody profiling. The core technology is utilized across a variety of offerings, including the flagship i-OMETM Discovery platform which boasts a library of 1800+ curated disease relevant auto-antibody targets.
Standard BioTools delivers leading solutions that enable researchers to discover unique biological insights. The San Francisco based company focuses on advancing drug development and patient care through collaboration with leading research institutions in areas like oncology and immunology.
Standard BioTools has been empowering pharmaceutical companies and leading research institutions to enhance disease understanding and accelerate biomarker discovery. By integrating Sengenics’ KREXTM precision antibody profiling, its proteomics offering will be further strengthened.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
About Sengenics
Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
About Summa
Founded in 2016, Summa is an impact investor focusing on three thematic areas: Resource Efficiency, Changing Demographics, and Tech-Enabled Transformation. The purpose of Summa is to invest in solving our global challenges.
Summa has c. EUR 5 billion in assets under management and has made over 30 platform investments across the three funds raised to date. Investments have the potential for long-term sustainable outperformance because they address some of the social, environmental, and governmental challenges we need to solve as a society.
The team is located in Northern Europe, with offices in Stockholm, Oslo, and Munich. Summa earned its certified B Corporation status in 2021, joining a growing group of companies reinventing business by pursuing purpose and profit.
For interviews or more information, please contact:
Hannah Gunvor Jacobsen, COO and Head of IR at Summa Equity
+47 936 41 960 | hannah.jacobsen@summaequity.com
The Summa Summarum newsletter
Sign up to our newsletter
Latest readings
Readings
Summa Equity merges Sengenics into Standard BioTools to broaden its proteomics offering
Read more
Summa Summit and 2024 Annual Investor Meeting
Read more
Summa Equity invests in EA Technology to accelerate the energy transition through a smarter grid
Read more
Investing in sustainable aquaculture for a resilient food system
Read more
Summa Equity acquires NetGuardians to create next generation financial crime solution
Read more